Telix Pharmaceuticals is a dynamic and rapidly growing radiopharmaceutical company headquartered in Australia, with additional offices in Belgium, Japan, Switzerland, and the United States. The company is dedicated to advancing precision medicine through targeted radiation therapies aimed at improving the quality of life for individuals affected by cancer and rare diseases. Telix is focused on the international rollout of its prostate cancer imaging agent and the development of late clinical-stage products that address significant unmet medical needs in oncology and rare diseases. With a commitment to excellence, innovation, and ethical practices, Telix fosters a collaborative and inclusive work environment, offering competitive salaries and support for employee development.